The co-founders of Darwin Health argue that the fight against pancreatic cancer has only just begun, even as new treatments show promise. Writing in STAT News, they stress that achieving dramatic progress will require sustained effort and investment.
Pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate below 10%. Recent breakthroughs, including targeted therapies like daraxonrasib, have raised hopes, but the authors say these are steps, not a finish line.
Darwin Health, a firm focused on AI-driven drug discovery, has been involved in developing treatments for the disease. The co-founders emphasize that translating early wins into widespread patient benefit demands rigorous clinical trials and deeper biological understanding.
A key challenge is tumor heterogeneity, which makes pancreatic cancer resistant to many therapies. The authors call for more research into combination treatments and early detection methods.
Without sustained funding and collaboration, the promise of recent advances could stall. The real work, they conclude, is just starting.